Pancreatic Cancer Research

ResearcherKansai Medical UniversityActive in the last 2 years

Tamotsu Kuroki

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5108370358. Sources: OpenAlex.

Their work

Papers
10 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
54
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: 2 papers · 2016: 1 paper · 2017: 1 paper · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 1 paper

Papers 10

  1. Three Molecular Developmental Pathways of Remnant Pancreatic Cancer After Resection: A Nationwide Project Study of Japan Pancreas Society. Co-author DOI 10.1097/sla.0000000000006444↗
  2. Impact of S-1 adjuvant chemotherapy longer than 6 months on survival in patients with resected pancreatic cancer: a nationwide survey by the Japan Pancreas Soc… Co-author DOI 10.1002/cncr.34580↗
  3. Prognostic Impact of Relative Dose Intensity of Adjuvant Chemotherapy With S-1 on Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.21873/anticanres.15802↗
  4. Optimal Treatment for Octogenarians With Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: A Multicenter Retrospective Study. Co-author DOI 10.1097/mpa.0000000000001579↗
  5. Prognostic importance of peritoneal washing cytology in patients with otherwise resectable pancreatic ductal adenocarcinoma who underwent pancreatectomy: A nat… Co-author DOI 10.1016/j.surg.2019.06.023↗
  6. No-touch isolation techniques for pancreatic cancer. Co-author DOI 10.1007/s00595-016-1317-5↗
  7. Clinicopathological Characteristics of Young Patients With Pancreatic Cancer: An Analysis of Data From Pancreatic Cancer Registry of Japan Pancreas Society. Co-author DOI 10.1097/mpa.0000000000000636↗
  8. Increased expression of PHD3 represses the HIF-1 signaling pathway and contributes to poor neovascularization in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00535-014-1030-3↗
  9. Laparoscopic distal pancreatosplenectomy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00595-014-1021-2↗
  10. Evaluation of SOX9 expression in pancreatic ductal adenocarcinoma and intraductal papillary mucinous neoplasm. First author DOI 10.1097/mpa.0b013e318269d281↗

Closest collaborators

The 25 strongest of 54 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hisato Igarashi · 5 shared papers, 2016–2025 · strength 0.49
  2. Sohei Satoi · 5 shared papers, 2016–2025 · strength 0.49
  3. Hidetoshi Eguchi · 5 shared papers, 2016–2025 · strength 0.49
  4. Hiroki Yamaue · 5 shared papers, 2016–2025 · strength 0.49
  5. Masaji Tani · 5 shared papers, 2016–2025 · strength 0.49
  6. Atsushi Masamune · 5 shared papers, 2016–2025 · strength 0.49
  7. Tsutomu Fujii · 5 shared papers, 2016–2025 · strength 0.49
  8. Yoshiki Hirooka · 5 shared papers, 2016–2025 · strength 0.49
  9. Susumu Eguchi · 5 shared papers, 2013–2022 · strength 0.46
  10. Michiaki Unno · 4 shared papers, 2016–2025 · strength 0.40
  11. Tomohisa Yamamoto · 3 shared papers, 2020–2025 · strength 0.37
  12. Kazuichi Okazaki · 3 shared papers, 2019–2025 · strength 0.31
  13. Yoshifumi Takeyama · 2 shared papers, 2023–2025 · strength 0.29
  14. Yuichi Nagakawa · 2 shared papers, 2023–2025 · strength 0.29
  15. Satoshi Hirano · 2 shared papers, 2020–2025 · strength 0.24
  16. Takao Itoi · 3 shared papers, 2016–2020 · strength 0.20
  17. Takayuki Tanaka · 2 shared papers, 2015–2022 · strength 0.17
  18. Hajime Matsushima · 2 shared papers, 2015–2022 · strength 0.17
  19. Kenichi Hakamada · 1 shared paper, 2025 · strength 0.16
  20. Masayuki Furukawa · 1 shared paper, 2025 · strength 0.16
  21. Motokazu Sugimoto · 1 shared paper, 2025 · strength 0.16
  22. Shugo Mizuno · 1 shared paper, 2025 · strength 0.16
  23. Shuji Suzuki · 1 shared paper, 2025 · strength 0.16
  24. Yuki Sunagawa · 1 shared paper, 2025 · strength 0.16
  25. Minoru Kitago · 1 shared paper, 2025 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.